JNJ - Johnson & Johnson
One of the world's most diversified healthcare companies, spanning prescription pharmaceuticals, medical technology, and a legacy consumer brands portfolio.
Finlify Score
59.5 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$255.82
-3.66%
52W Range
$164.23 - $269.43
Market Cap
$611.4B
-3.7%Compared to previous day
2026 Q1 Revenue
$24.1B
-2.0%Changes from last reporting quarter
2026 Q1 EPS
$2.14
Diluted shares
Analyst Rating
31 analysts in latest ratings feed
RSI
48.9
40-70 moderate
2Y Range Position
86%
-6.9% from high / +81.8% from low
Beta
0.22
Relative to market benchmark
MACD
-0.10
MACD line 4.52 / signal line 4.63
Fundamental Trend
Growth 33.1Financial Health
Quality 75.7Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
HOLD59.5 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $24.1B-2.0% | $24.6B+2.4% | $24.0B+1.1% | $23.7B+8.5% |
| Gross Profit | $16.0B-3.9% | $16.6B-0.6% | $16.7B+3.6% | $16.1B+10.9% |
| Operating Income | - | - | - | - |
| Net Income | $5.2B+2.3% | $5.1B-0.7% | $5.2B-7.0% | $5.5B-49.7% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jul 25, 2026
Finlify's signal for JNJ is HOLD, with an overall score of 59.5/100, suggesting a balanced outlook driven by strong technical and financial quality components, but tempered by a weaker fundamental trend.
Technical
The asset appears to exhibit positive momentum, indicated by a Relative Strength score of 63.7/100 and an Accumulation / Volume score of 73.9/100. JNJ has seen a 7.6% return over 20 days and a 15.1% return over 60 days, with its RSI(14) at 59.5, suggesting it is not currently overbought. The asset is also trading only -3.0% from its 52-week high.
Fundamentals
While Financial Quality appears strong at 75.7/100, the Fundamental Trend score of 33.1/100 suggests some underlying weakness. The asset's valuation multiples, such as a P/E of 23.6x, P/B of 6.1x, and P/S of 6.7x, may indicate a premium valuation. JNJ also offers a dividend yield of 2.07% and has a low beta of 0.2, suggesting lower volatility.
Macro Context
In a macro environment with elevated inflation (CPI YoY at 3.7%, Core PCE YoY at 3.4%) and a 10Y Treasury Yield at 4.7%, JNJ's defensive characteristics and low beta of 0.2 may offer some stability, though higher interest rates could potentially impact future growth financing.
Key Risks
- The Fundamental Trend score of 33.1/100 suggests potential underlying weakness in fundamental drivers.
- Valuation multiples, including a P/E of 23.6x and P/B of 6.1x, may indicate the asset is trading at a premium.
- The asset's current price is only -3.0% from its 52-week high, which could suggest limited immediate upside potential.